Io Therapeutics, Inc. was founded to develop and commercialize a series of retinoid and rexinoid compounds originally discovered at Allergan, Inc. by Rosh Chandraratna, one of Io Therapeutics’ founders. The company’s strategy includes expanding the uses of the compounds in its pipeline to address new indications. IRX4204, an RXR agonist originally developed for treatment of cancers, is being developed for neurodegenerative and autoimmune diseases. IRX4310, an RAR antagonist originally developed for dermatologic diseases is being developed for prophylaxis of chemotherapy-induced neutropenia. IRX5183, an RARα agonist originally developed for treatment of cancers, is being developed as a treatment for autoimmune diseases.